These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 3085844)
1. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. Atsukawa M; Tsubota A; Takaguchi K; Toyoda H; Iwasa M; Ikegami T; Chuma M; Nozaki A; Uojima H; Hiraoka A; Fukunishi S; Yokohama K; Tada T; Kato K; Abe H; Tani J; Okubo H; Watanabe T; Hattori N; Tsutsui A; Senoh T; Yoshida Y; Okubo T; Itokawa N; Nakagawa-Iwashita A; Kondo C; Arai T; Michitaka K; Iio E; Kumada T; Tanaka Y; Takei Y; Iwakiri K J Gastroenterol Hepatol; 2020 Jul; 35(7):1229-1237. PubMed ID: 31881554 [TBL] [Abstract][Full Text] [Related]
2. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320 [TBL] [Abstract][Full Text] [Related]
3. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. Gallo A; Dedionigi C; Civitelli C; Panzeri A; Corradi C; Squizzato A J Transl Int Med; 2020 Dec; 8(4):220-236. PubMed ID: 33511049 [TBL] [Abstract][Full Text] [Related]
4. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. Ballester MR; Roig E; Gich I; Puntes M; Delgadillo J; Santos B; Antonijoan RM Drug Des Devel Ther; 2015; 9():4291-302. PubMed ID: 26273191 [TBL] [Abstract][Full Text] [Related]
5. Cirrhosis and its complications: evidence based treatment. Nusrat S; Khan MS; Fazili J; Madhoun MF World J Gastroenterol; 2014 May; 20(18):5442-60. PubMed ID: 24833875 [TBL] [Abstract][Full Text] [Related]
6. Sympatho-renal axis in chronic disease. Sobotka PA; Mahfoud F; Schlaich MP; Hoppe UC; Böhm M; Krum H Clin Res Cardiol; 2011 Dec; 100(12):1049-57. PubMed ID: 21688196 [TBL] [Abstract][Full Text] [Related]
7. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Møller S; Henriksen JH; Bendtsen F Hepatol Int; 2008 Dec; 2(4):416-28. PubMed ID: 19669317 [TBL] [Abstract][Full Text] [Related]
8. Guidelines on the management of ascites in cirrhosis. Moore KP; Aithal GP Gut; 2006 Oct; 55 Suppl 6(Suppl 6):vi1-12. PubMed ID: 16966752 [No Abstract] [Full Text] [Related]
10. Renal tubular events following passage from the supine to the standing position in patients with compensated liver cirrhosis: loss of tubuloglomerular feedback. Sansoè G; Biava AM; Silvano S; Ferrari A; Rosina F; Smedile A; Touscoz A; Bonardi L; Rizzetto M Gut; 2002 Nov; 51(5):736-41. PubMed ID: 12377816 [TBL] [Abstract][Full Text] [Related]
12. Which diuretic to use? Swanepoel CR Cardiovasc Drugs Ther; 1994 Feb; 8(1):123-8. PubMed ID: 8086322 [TBL] [Abstract][Full Text] [Related]
13. Loop diuretics versus others in the treatment of congestive heart failure after myocardial infarction. Reyes AJ Cardiovasc Drugs Ther; 1993 Dec; 7(6):869-76. PubMed ID: 8011561 [TBL] [Abstract][Full Text] [Related]
14. Combined use of water immersion and frusemide in treatment of resistant ascites in liver cirrhosis. Fawthrop F; O'Hare JP; Millar N; Weston CF; Read AE J R Soc Med; 1987 Dec; 80(12):776-7. PubMed ID: 3430532 [No Abstract] [Full Text] [Related]
15. The influence of posture on the response to loop diuretics in patients with chronic cardiac failure is reduced by angiotensin converting enzyme inhibition. Flapan AD; Davies E; Waugh C; Williams BC; Shaw TR; Edwards CR Eur J Clin Pharmacol; 1992; 42(6):581-5. PubMed ID: 1623897 [TBL] [Abstract][Full Text] [Related]